![](https://endpts.com/wp-content/uploads/2021/07/John-Houston-Arvinas-tile-scaled.jpg)
John Houston, Arvinas CEO
Arvinas gets $350M boost from investors to extend runway into 2027
Arvinas’ $350 million private placement will help bankroll the protein degrader biotech as it nears completion of its first Phase III study with partner Pfizer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.